Conventional Non-Penetrating Deep Sclerectomy Versus Modified Subflap Mattress Suture in OAG

February 14, 2026 updated by: Dr Amr Taha Orabi, Beni-Suef University

Comparison Between Conventional Non-Penetrating Deep Sclerectomy and Modified Technique With Subflap Mattress Suture in Patients With Open-Angle Glaucoma

The goal of this clinical trial is to learn if modified non-penetrating deep sclerectomy (NPDS) with a sub-flap mattress suture works to treat open-angle glaucoma (OAG). It will also learn about the safety and effectiveness of this modified surgical approach. The main questions it aims to answer are:

Does the modified NPDS technique result in significantly lower and more persistent intraocular pressure (IOP) reduction compared to the conventional technique? What is the rate of complete success (IOP 6-18 mmHg without medication) and qualified success (IOP 6-18 mmHg with medication) for both groups? What postoperative complications or medical problems (such as iris prolapse, conjunctival leaks, or IOP spikes) do participants experience?

Researchers will compare Modified Deep Sclerectomy with Ahmed's sub-flap mattress suture to standard conventional NPDS to see which technique provides better long-term pressure control.

Participants will be randomized into two groups and will:

Undergo either the standard NPDS procedure or the modified NPDS procedure using a 10/0 nylon mattress suture.

Visit the clinic for at least five scheduled follow-up appointments at 1 week, 1 month, 3 months, 6 months, and 9 months post-surgery.

Undergo comprehensive eye examinations at each visit, including Goldmann applanation tonometry for IOP, visual acuity testing, and monitoring for the development of cataracts or other surgical complications.

Study Overview

Detailed Description

The surgical protocol for Non-Penetrating Deep Sclerectomy (NPDS) begins with standardized aseptic preparation using 10% and 5% Betadine, followed by peribulbar anesthesia. In the standard Group 1 procedure, a 4 mm x 4 mm superficial scleral flap is created after conjunctival dissection, and Mitomycin-C (0.2 mg/mL) is applied for two minutes to inhibit scarring. The core of the surgery involves dissecting a deeper scleral flap to 90% thickness, unroofing Schlemm's canal to expose the trabeculo-descemet's membrane (TDM) and allow for aqueous percolation. The deep flap is then excised, the superficial flap is sutured with 10/0 nylon, and the conjunctiva is closed with watertight 7/0 Vicryl sutures.

For Group 2, the standard NPDS steps were followed until the excision of the deep scleral flap, at which point a specific mattress suture modification is introduced. Utilizing the Abdel Rahman and Habib technique, a 10/0 nylon suture is threaded through the sclera 2 mm lateral to the flap borders in an anteroposterior and postero-anterior fashion, creating a mattress configuration beneath the superficial flap to maintain the filtration space. Postoperatively, both groups follow a strict regimen of topical moxifloxacin and prednisolone acetate, which is tapered over six weeks, alongside a five-day course of oral ciprofloxacin to prevent infection and manage inflammation.

Study Type

Interventional

Enrollment (Actual)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Beni Suweif Governorate
      • Banī Suwayf, Beni Suweif Governorate, Egypt, 62511
        • Beni-suef university Hospital
    • Giza Governorate
      • Giza, Giza Governorate, Egypt
        • The Glaucoma Department at the Memorial Institute for Ophthalmic Research

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with primary or secondary open-angle glaucoma (OAG), either uncontrolled or intolerant to medical therapy

Exclusion Criteria:

  • Past glaucoma procedures, including laser therapy, lens extraction, previous refractive surgery, angle closure, and neovascular glaucoma.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Group A (Conventional NPDS)
The standard procedure
The conjunctiva was made more visible by placing a 7/0 Vicryl corneal traction suture in the superior cornea. Wescott scissors were used to excise a 10 mm fornix-based conjunctival flap, and minimum diathermy was used to achieve haemostasis. Using a super blade, a 4 mm x 4 mm superficial scleral flap was made. Then, a crescent knife was used for anterior dissection to a depth of around 50% of the scleral thickness, exposing the top 2 mm of the transparent cornea. Under the scleral flap in the subconjunctival area, mitomycin-C (MMC®) sponges were positioned at a concentration of 0.2 mg/mL and moved towards the upper fornix. They were kept in place for 2 minutes. A balanced salt solution, volume 50 mL, was used for irrigation purposes. The scleral spur was located by dissecting a deep scleral flap that began at the superficial flap's perimeter and continued to a depth equal to 90% of the thickness of the scleral bed. To expose the trabecular meshwork (TDM), the roof of Schlemm's canal wa
Experimental: Group B (Modified NPDS)
Modified NPDS with Ahmed's sub-flap mattress suture
Up until the deep scleral flap was removed, this method was identical to the conventional NPDS. Applying a mattress suture beneath the superficial scleral flap was the next step. The superficial flap was sutured with a 10/0 nylon (Alcon®) that extended 1 mm beyond its outside edges. The methodology originally described by Abdel Rahman and Habib was followed by the placement method. The initial step in introducing the suture into the sclera was to line it with the left boundary of the superficial scleral flap and to do it in an anteroposterior manner. This was done 2 mm outside the flap. After that, it was moved horizontally under the flap again until it reached the right border. Then, it was threaded postero-anteriorly, 2 mm laterally to the right flap edge. Then, using McPherson forceps, the suture was fastened in a mattress configuration, with one limb placed near Schlemm's canal.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intraocular Pressure (IOP)
Time Frame: From baseline (1 day preoperative) to the five follow-up visits at one week, one month, three months, six months, and nine months.
IOP was measured using Goldmann applanation tonometry (GAT) at baseline (1 day preoperative) and during the planned follow-up visits.
From baseline (1 day preoperative) to the five follow-up visits at one week, one month, three months, six months, and nine months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Percentage of Patients with Postoperative IOP within 6-18 mmHg without Medication
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
If the intraocular pressure (IOP) stayed within the 6-18 mmHg range without medication throughout the follow-up period, the surgical result was deemed a full success. Reaching the same intraocular pressure (IOP) range while using topical medicines was considered a qualified success. Failure was defined as the inability to meet any of these requirements, which might lead to problems that could impair vision or need more severe glaucoma surgery.
At one week, one month, three months, six months, and nine months postoperatively.
Best Corrected Visual Acuity (BCVA)
Time Frame: From baseline 1 day preoperative and the five follow-up visits at one week, one month, three months, six months, and nine months.
Measured using Snellen's chart to assess baseline BCVA and any changes following the surgical procedure.
From baseline 1 day preoperative and the five follow-up visits at one week, one month, three months, six months, and nine months.
Postoperative Complications
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
Postoperative complications, such as iris prolapse, conjunctival leak, or IOP spikes, were assessed and compared between the two study groups.
At one week, one month, three months, six months, and nine months postoperatively.
Need for Reintervention
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
The need for intervention with bleb needling or YAG goniopuncture was assessed between the conventional and modified NPDS groups.
At one week, one month, three months, six months, and nine months postoperatively.
Postoperative Medication
Time Frame: At one week, one month, three months, six months, and nine months postoperatively.
The use of postoperative medications was evaluated and reported in the form of 'no drugs', 'one drug,' or 'two drugs' between the two study groups.
At one week, one month, three months, six months, and nine months postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Amr Taha Orabi, Beni-Suef University
  • Study Director: Mohamed Sayed Abouzeid, MD, Beni-Suef University
  • Study Chair: Hazem Haroun, Beni-Suef University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 7, 2022

Primary Completion (Actual)

August 1, 2024

Study Completion (Actual)

August 1, 2024

Study Registration Dates

First Submitted

February 2, 2026

First Submitted That Met QC Criteria

February 14, 2026

First Posted (Actual)

February 23, 2026

Study Record Updates

Last Update Posted (Actual)

February 23, 2026

Last Update Submitted That Met QC Criteria

February 14, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Open Angle Glaucoma (OAG)

Clinical Trials on Conventional Nonpenetrating Deep Sclerectomy (NPDS)

Subscribe